MacroGenics, Inc. (FRA:M55)

Market Cap	91.28M -49.2%
Revenue (ttm)	108.78M -9.7%
Net Income	-64.68M
EPS	-1.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.458
Previous Close	1.424
Day's Range	1.458 - 1.458
52-Week Range	0.900 - 2.752
Beta	n/a
RSI	51.11
Earnings Date	Mar 6, 2026

About MacroGenics

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 341
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: M55

Financial Performance

In 2024, MacroGenics's revenue was $149.96 million, an increase of 155.26% compared to the previous year's $58.75 million. Losses were -$66.97 million, 639.3% more than in 2023.

Financial numbers in USD